These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35071151)

  • 1. Let's End HepC: Modelling Public Health Epidemiological Policies Applied to Hepatitis C in Spain.
    Lopes H; Baptista-Leite R; Franco D; Serra MA; Escudero A; Martín-Moreno JM
    Front Public Health; 2021; 9():735572. PubMed ID: 35071151
    [No Abstract]   [Full Text] [Related]  

  • 2. Integrating public health policies in the epidemiological modeling of hepatitis C with LEHC tool: application in Austria.
    Lopes H; Baptista-Leite R; Franco D; Pirker R; Gschwantler M
    Wien Klin Wochenschr; 2021 May; 133(9-10):461-469. PubMed ID: 33331968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the Puzzle of Hepatitis C Epidemiology in Romania: A Pathway to Control.
    Lopes H; Baptista-Leite R; Franco D; Eclemea I; Bratu EC; Furtunescu FL; Pop CS; Pana BC
    J Gastrointestin Liver Dis; 2020 Sep; 29(3):377-384. PubMed ID: 32830821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
    Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
    J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis.
    Gamkrelidze I; Pawlotsky JM; Lazarus JV; Feld JJ; Zeuzem S; Bao Y; Gabriela Pires Dos Santos A; Sanchez Gonzalez Y; Razavi H
    Liver Int; 2021 Mar; 41(3):456-463. PubMed ID: 33389788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global timing of hepatitis C virus elimination in high-income countries.
    Razavi H; Sanchez Gonzalez Y; Yuen C; Cornberg M
    Liver Int; 2020 Mar; 40(3):522-529. PubMed ID: 31815353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
    Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
    BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.
    Polaris Observatory HCV Collaborators
    Lancet Gastroenterol Hepatol; 2022 May; 7(5):396-415. PubMed ID: 35180382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
    Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
    Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cascade of care during the first 36 months of the treatment as prevention for hepatitis C (TraP HepC) programme in Iceland: a population-based study.
    Olafsson S; Fridriksdottir RH; Love TJ; Tyrfingsson T; Runarsdottir V; Hansdottir I; Bergmann OM; Björnsson ES; Johannsson B; Sigurdardottir B; Löve A; Baldvinsdottir GE; Hernandez UB; Gudnason T; Heimisdottir M; Hellard M; Gottfredsson M
    Lancet Gastroenterol Hepatol; 2021 Aug; 6(8):628-637. PubMed ID: 34171267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
    Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
    PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain.
    Crespo J; Cuadrado A; Perelló C; Cabezas J; Llerena S; Llorca J; Cedillo S; Llop E; Escudero MD; Hernández Conde M; Puchades L; Redondo C; Fortea JI; Gil de Miguel A; Serra MA; Lazarus JV; Calleja JL
    J Viral Hepat; 2020 Apr; 27(4):360-370. PubMed ID: 31755634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is hepatitis C virus (HCV) elimination achievable among people who inject drugs in Tijuana, Mexico? A modeling analysis.
    Marquez LK; Cepeda JA; Bórquez A; Strathdee SA; Gonzalez-Zúñiga PE; Fleiz C; Rafful C; Garfein RS; Kiene SM; Brodine S; Martin NK
    Int J Drug Policy; 2021 Feb; 88():102710. PubMed ID: 32165050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global prevalence of hepatitis C virus in children in 2018: a modelling study.
    Schmelzer J; Dugan E; Blach S; Coleman S; Cai Z; DePaola M; Estes C; Gamkrelidze I; Jerabek K; Ma S; Montoya S; Razavi-Shearer D; Razavi-Shearer K; Robbins-Scott S; Razavi H; El Sayed MH
    Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):374-392. PubMed ID: 31954439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach.
    Busschots D; Ho E; Blach S; Nevens F; Razavi H; Van Damme B; Vanwolleghem T; Robaeys G
    BMC Infect Dis; 2022 Apr; 22(1):397. PubMed ID: 35459120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care.
    Lazarus JV; Herranz A; Picchio CA; Villota-Rivas M; Rodríguez A; Alonso JM; Moratinos A; Perrotta A; Tegeo E; Bibiloni F; Buti M; Vilella À
    BMJ Open; 2021 Oct; 11(10):e053394. PubMed ID: 34675021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study.
    European Union HCV Collaborators
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):325-336. PubMed ID: 28397696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
    Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
    J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.